Related Experiment Video

Updated: Jun 20, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Cot/Tpl-2 protein kinase as a target for the treatment of inflammatory disease

D George1, A Salmeron

  • 1Abbott Bioresearch Center, Worcester, MA 01605, USA. dawn.george@abbott.com

Current Topics in Medicinal Chemistry
|August 20, 2009
PubMed

Insights

Cot/Tpl-2 kinase is crucial for inflammatory responses in macrophages, driving cytokine production linked to autoimmune diseases like rheumatoid arthritis. Inhibiting this kinase offers potential new treatments for these conditions.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Cot/Tpl-2 (MAP3K8) is a serine/threonine kinase vital for macrophage inflammatory responses.
  • It mediates lipopolysaccharide (LPS)-induced MEK/ERK pathway activation.
  • Dysregulated cytokine production, including TNF and IL-1beta, is implicated in autoimmune diseases.

Purpose of the Study:

  • To review the physiological role of Cot/Tpl-2 in inflammation.
  • To explore the therapeutic potential of Cot/Tpl-2 inhibitors for autoimmune diseases.
  • To summarize the current landscape of small molecule Cot/Tpl-2 inhibitors.

Main Methods:

  • Review of existing literature on Cot/Tpl-2 function and inhibition.
  • Analysis of Cot/Tpl-2's role in LPS-induced inflammatory pathways.
  • Examination of clinical implications in autoimmune disease models.

Main Results:

  • Cot/Tpl-2 deficiency impairs LPS-induced MEK/ERK activation in macrophages.
  • Cot/Tpl-2 kinase activity is essential for pro-inflammatory cytokine production (TNF, IL-1beta).
  • Elevated cytokines are linked to rheumatoid arthritis pathogenesis.

Conclusions:

  • Cot/Tpl-2 is a key regulator of inflammation and cytokine production in macrophages.
  • Inhibition of Cot/Tpl-2 kinase presents a promising therapeutic strategy for autoimmune diseases.
  • Further research into Cot/Tpl-2 inhibitors could yield novel treatments for rheumatoid arthritis.

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...